Formoterol (OXIS®) Turbuhaler® as A Rescue Therapy Compared with Salbutamol pMDI Plus Spacer in Patients with Acute Severe Asthma
W Boonsawat, S Charoenratanakul, C Pothirat, K Sawanyawisuth, T Seearamroongruang, T Bengtsson, R Brander, O Selroos
Srinagarind Hospital, Khon Kaen, Thailand. E-mail: Fax: +66-043-241-735
Formoterol has a similar onset of effect to salbutamol but a prolonged duration of action. However, the relative efficacy of the two drugs in acute severe asthma is not known. This double-blind, double-dummy study compared the safety and efficacy of the maximum recommended daily dose of formoterol and a predicted equivalent dose of salbutamol in 88 patients presenting to the emergency department with acute severe asthma. Patients were randomized to formoterol 54 μg via Turbuhaler® or salbutamol 2400 μg via pressurized metered dose inhaler (pMDI) plus spacer in three equal doses over 1h. Following the full dose, mean FEV1 at 75 min increased by 37% for formoterol and 28% for salbutamol (P=0.18). The maximum increase in FEV1 over 4 h was significantly greater with formoterol compared with salbutamol (51% vs. 36%, respectively P<0.05) and formoterol was as effective as salbutamol at improving symptoms and wellbeing. Both treatments were well tolerated. Formoterol caused a greater decrease in serum potassium (difference –0.2 mmol/l). In severe acute asthma, bronchodilator therapy with high-dose (54 μg) formoterol Turbuhaler provided equally rapid improvements in lung function of greater magnitude over 4h than high-dose (2400 μg) salbutamol pMDI plus spacer.
ปี 2546, September ปีที่: 97 ฉบับที่ 9 หน้า 1067-1074
Acute severe asthma, Formoterol Turbuhaler, Reliever medication, Salbutamol pMDI plus spacer